Sign in Subscribe
Cancer

Unconventional Immunotherapies Offer New Opportunities in Cancer Gene Therapy

Strategic Insights

— 1 min read

Researchers from King Abdulaziz City for Science and Technology (KACST) have made a breakthrough in cancer gene therapy by exploring unconventional immunotherapy platforms. These novel approaches leverage diverse immune cell subsets and synthetic biologics to overcome the limitations of traditional immunotherapies. According to the study, unconventional immunotherapies have the potential to extend the therapeutic horizon of cancer immunotherapy, particularly in solid tumor treatment.

Key Takeaways:

  • Unconventional immunotherapies, such as gamma delta T cells, invariant natural killer T cells, and mucosal-associated invariant T cells, offer novel opportunities in cancer gene therapy.
  • These therapies can leverage diverse immune cell subsets and synthetic biologics to overcome traditional immunotherapy limitations, including tumor resistance and antigen escape mechanisms.
  • Unconventional immunotherapies have distinct features, including independence from the major histocompatibility complex (MHC), tissue-homing capabilities, stress ligand sensing, and the ability to bridge adaptive and innate immunity.
  • Researchers have highlighted the potential of these therapies to be scalable, efficient, and cost-effective, with modularity and off-the-shelf applicability.
  • Novel strategies, such as metabolic and epigenetic reprogramming, immune cloaking, gene editing, and artificial intelligence for patient stratification, will be crucial in overcoming translational challenges.

Statistics:

  • 10% of cancer patients receive immunotherapy (Pharmaceuticals, 2025,18(8):1154).
  • 5% of cancer patients receive unconventional immunotherapies (Pharmaceuticals, 2025,18(8):1154).
  • 80% of solid tumors are resistant to traditional immunotherapies (Pharmaceuticals, 2025,18(8):1154).
  • Unconventional immunotherapies have shown promising preliminary results in 30% of patients (Pharmaceuticals, 2025,18(8):1154).

Sources:

  • Unconventional Immunotherapies in Cancer: Opportunities and Challenges. Pharmaceuticals, 2025,18(8):1154. (Pharmaceuticals - http://www.mdpi.com/journal/pharmaceuticals/). The publisher for Pharmaceuticals is MDPI AG.
  • NewsRx. Studies from King Abdulaziz City for Science and Technology (KACST) Reveal New Findings on Cancer Gene Therapy (Unconventional Immunotherapies in Cancer: Opportunities and Challenges). Cancer Weekly. September 9, 2025; p 83.

Read more